(Chem. Pharm. Bull. 20(1) 206-208 (1972)]

UDC 547.835.1.057.09:615.281.011.5.076.7


Synthesis of Some N,N'-Bis-(9-acridino)- α,ω -diaminoalkanes Dihydrochloride as Potential Antibacterial, Antitubercular and Antileprotics

S.M. DESHPANDE and A.K. SINGH


Department of Chemistry, Faculty of Science, Banaras Hindu University¹)

(Received January 1, 1971)

The drugs used in the treatment of tuberculosis are isoniazid,²⁾ streptomycin^{3,4)} and PAS⁵) and regarding the treatment of leprosy, DDS(I) (diaminodiphenyl sulphone).⁶) thiosemicarbazones,⁷⁾ 4,4'-diethoxydiphenyl thiourea⁸⁾ (II), chaulmoogra oil (III) and hydnocarpic oil (III) are widely popular. Since a variety of compounds (vide supra) show such activity and the last two particularly contain a polymethylene chain, it was considered of sufficient interest to investigate a new system of compounds with the general structure (IV), R-NH-(CH₂)_n-NH-R (R=9-acridino) incorporating both the polymethylene characteristic of III and basic characteristic of DDS. This forms the subject matter of the present communication.



The preparation of this general type (IV) was accomplished according to the scheme:



9-Chloroacridine⁹⁾ required was obtained by reaction of POCl₃ with diphenylamine-2carboxylic acid.¹⁰⁾ Reaction of 9-chloroacridine with an appropriate diamine at $130-135^{\circ}$ in phenol¹¹) furnished (IV) directly as the dihydrochloride.

The compounds mentioned in Table I were studied for their antibacterial, antitubercular

- 3) A.B.A. Karat, P.S.S. Rao, Mrs. S. Karat and C.K. Job, Lep. Rev., 38, 3, 169-170 (1967).
- 4) A. Schatz, E. Bugie and S.A. Waksman, Proc. Soc. Exp. Biol. N.Y., 55, 66 (1944).

- 8) N.P. Buu-Hoi and N.D. Xuong, C.R. Acad. Sci. Paris, 237, 498 (1953).
- 9) A. Albert, "The Acridines," Edward Arnold & Co., London, 1951, p. 38.
 10) A. Albert, "The Acridines," Edword Arnold & Co., London, 1951, p. 54.
- 11) A.R. Surrey and R.A. Cutler, J. Am. Chem. Soc., 73, 2623 (1951).

¹⁾ Location: Varanasi-5, India.

²⁾ H. Meyer and J. Malley, Mh. Chem., 33, 393 (1912).

⁵⁾ J. Lehmann, Lancet, 1, 14 (1946).

⁶⁾ R.G. Cochrane, Brit. Med. J., 2, 1220 (1952).

⁷⁾ G. Domak, Beitr. Klin. Tuberk., 101, 365 (1948).

and antileprotic activities according to the procedures given in "Experimental."

The activity against S. aureus and E. coli is substantial with chain lengths having n=3 and 5 and is nil with all other values of n. The activity of these compounds against M. tvberculosis is appreciable only at 10^{-4} molar concentration (vide Table I). Compounds containing a chain length of n=3,8,10 and 12 are found active against M. leprae (Table I).

	Antibacterial activity (Net values)									
Compound No.	Structure HN-(CH ₂) _n -NH · 2HCl			0.1 ml of 10 ⁻² molar solution of the compound in water by Cup-plate method. Diameter of cup is 10 mm						
	R R			strain	S. aureus	strain E. coli				
	n		R	Compound	5% phenol control	Compound	5% phenol control			
1	2	9-a	cridino	-ve	7 mm	-ve	8 mm			
2	3	9-a	cridino	$7 \mathrm{mm}$	$7 \mathrm{mm}$	$7 \mathrm{mm}$	8 mm			
3	4	9-a	cridino	-ve	7 mm	-ve	8 mm			
4	5	9-a	cridino	$9~\mathrm{mm}$	13 mm	4 mm 10 mm				
5	6	9-a	cridino	-ve	$21 \mathrm{~mm}$	-ve	12 mm			
6	7	9-a	cridino	-ve	8 mm	-ve	6 mm			
7	8	9-a	cridino	-ve	8 mm	-ve	6 mm			
8	9	9-a	cridino	-ve	8 mm	-ve	6 mm			
9	10	9-a	cridino	-ve	8 mm	-ve	6 mm			
10	12	9-a	cridino	-ve	8 mm	-ve	6 mm			
				0.1 ml of	18 hr old cul	ture				
Ā			• •	H37Rv strain)		leprotic activ	ity			
	Growth		n's medi		Anti	leprotic activ	-			
Compound	Growth end of th	in Youma hree weeks	n's medi s	H37Rv strain) um at the	Anti	leprotic activ	-			
	Growth end of th	in Youma	n's medi s	H37Rv strain) um at the	Anti	leprotic activ	st			
Compound	Growth end of th	in Youma hree weeks	n's medi s	H37Rv strain) um at the	Anti	leprotic activ reening agains M. leprae	st			
Compound No.	Growth end of th Conce	in Youma hree weeks entration o	n's medi s of drug (2 10 ⁶ ##	H37Rv strain) um at the Molar) Rv control ## n	Anti Scr (I 10 activity upt	leprotic activ reening agains <i>M. leprae</i> .C.R.C. strain to 400 μg/ml o	st) concentration			
Compound No.	Growth end of th Conce 10 ⁻⁴	in Youma hree weeks entration of 10^{-5} \ddagger 0	n's medi s of drug (2 10 ⁶ ## ##	H37Rv strain) um at the Molar) Rv control ## n ## a	Anti Scr (Ι ο activity up4 ctive at 100 μ	leprotic activ reening agains <i>M. leprae</i> .C.R.C. strain to 400 μg/ml o g/ml concent:	st) concentration ration			
Compound No.	Growth end of th Conce 10 ⁻⁴	in Youma hree weeks entration of 10 ⁻⁵ 	n's medi s of drug (2 10 ⁶ ## ##	H37Rv strain) um at the Molar) Rv control ## n ## a ## n	Anti Scr (Ι ο activity up4 ctive at 100 μ ο activity up4	leprotic activ reening agains <i>M. leprae</i> .C.R.C. strain to 400 μg/ml o g/ml concent: to 400 μg/ml o	concentration ration			
Compound No. 1 2 3 4	Growth end of th Conce 10 ⁻⁴ + 0 0 0	in Youma hree weeks entration of 10^{-5} \ddagger 0	n's medi s of drug (1 10 ⁶ ## ## ##	H37Rv strain) um at the Molar) Rv control ## n ## a ## n ## n	Anti Scr (I to activity up4 .ctive at 100 µ to activity up4 to activity up4	leprotic activ reening agains M. leprae .C.R.C. strain to 400 μ g/ml o .g/ml concent: to 400 μ g/ml o to 400 μ g/ml o	concentration ration concentration concentration			
Compound No. 1 2 3 4 5	Growth end of tl Conce 10 ⁻⁴ + 0 0 0 0 0	in Youma hree weeks entration of 10^{-5} $\frac{10^{-5}}{10^{-5}}$ $\frac{10^{-5}}{10^{-5}}$ $\frac{10^{-5}}{10^{-5}}$	n's medi s of drug (10 ⁶ ## ## ## ##	H37Rv strain) um at the Molar) Rv control ## n ## n ## n ## n ## n ## n	Anti Sci (I to activity up active at 100 µ to activity up to activity up to activity up	leprotic activ reening agains M. leprae C.R.C. strain to 400 μ g/ml o to 400 μ g/ml o to 400 μ g/ml o to 400 μ g/ml o	st) concentration ration concentration concentration			
Compound No. 1 2 3 4 5 6	Growth end of tl Conce 10-4 + 0 0 0 0 0 0 0	in Youma hree weeks ontration of 10 ⁻⁵ 	n's medi s of drug (1 10 ⁶ ## ## ## ## ##	H37Rv strain) um at the Molar) Rv control ## n ## n ## n ## n ## n ## n ## n ##	Anti Scr (Ι ο activity up ctive at 100 μ ιο activity up ιο activity up ιο activity up ιο activity up	leprotic activ reening agains M. leprae C.R.C. strain to 400 μ g/ml o to 400 μ g/ml o to 400 μ g/ml o to 400 μ g/ml o to 400 μ g/ml o	st) concentration concentration concentration concentration concentration			
Compound No. 1 2 3 4 5 6 7	Growth end of th Conce 10 ⁻⁴ + 0 0 0 0 0 0 0 +	in Youma hree weeks ontration of 10 ⁻⁵ ## 0 Sl # + # # #	n's medi s of drug (2 10 ⁶ ## ## ## ## ##	H37Rv strain) um at the Molar) Rv control ## n ## n ## n ## n ## n ## n ## n ##	Anti Scr (I to activity up ctive at 100 μ to activity up to activity up to activity up to activity up to activity up to activity up to activity up	leprotic activ reening agains M. leprae .C.R.C. strain to 400 μ g/ml of to 400 μ g/ml of	st) concentration concentration concentration concentration concentration ration			
Compound No. 1 2 3 4 5 6 7 8	Growth end of th Conce 10 ⁻⁴ + 0 0 0 0 0 0 0 + + +	in Youma hree weeks entration of 10 ⁻⁵ ## 0 SI # + # # # # #	n's medi of drug (10 ⁶ ## ## ## ## ## ##	H37Rv strain) um at the Molar) Rv control ## n ## n ## n ## n ## n ## n ## n ##	Anti Scr (I to activity up to activity up	leprotic activ reening agains M. leprae C.R.C. strain to 400 μ g/ml o to 400 μ g/ml o	st) concentration concentration concentration concentration ration concentration			
Compound No. 1 2 3 4 5 6 7 8 9	Growth end of th Conce 10 ⁻⁴ + 0 0 0 0 0 0 + + + + + + + + +	in Youma hree weeks entration of 10 ⁻⁵ ## 0 S1 # # # # # # # # # # # #	n's medi of drug (10 ⁶ # # # # # # # # # #	H37Rv strain) um at the Molar) Rv control ## n ## n ## n ## n ## n ## n ## n ##	Anti Scr (I to activity up to activity up	leprotic activ reening agains M. leprae C.R.C. strain to 400 μ g/ml of g/ml concent to 400 μ g/ml of to 400 μ g/ml of to 400 μ g/ml of to 400 μ g/ml of to 400 μ g/ml of g/ml concent to 400 μ g/ml of g/ml concent	concentration concentration concentration concentration concentration concentration ration			
Compound No. 1 2 3 4 5 6 7 8	Growth end of th Conce 10 ⁻⁴ + 0 0 0 0 0 0 0 + + +	in Youma hree weeks entration of 10 ⁻⁵ ## 0 SI # + # # # # #	n's medi of drug (10 ⁶ ## ## ## ## ## ##	H37Rv strain) um at the Molar) Rv control ## n ## n ## n ## n ## n ## n ## n ##	Anti Scr (I to activity up to activity up	leprotic activ reening agains M. leprae C.R.C. strain to 400 μ g/ml of g/ml concent to 400 μ g/ml of to 400 μ g/ml of to 400 μ g/ml of to 400 μ g/ml of to 400 μ g/ml of g/ml concent to 400 μ g/ml of g/ml concent	concentration concentration concentration concentration concentration concentration ration			
Compound No. 1 2 3 4 5 6 7 8 9	Growth end of th Conce 10 ⁻⁴ + 0 0 0 0 0 0 + + + + 0 0 0 0 + + + +	in Youma hree weeks entration of 10 ⁻⁵ ## 0 S1 # # # # # # # # # # # #	n's medi of drug (10 ⁶ ## ## ## ## ## ##	H37Rv strain) um at the Molar) Rv control ## n ## n ## n ## n ## n ## n ## n ##	Anti Scr (I to activity upf ctive at 100 µ to activity upf to activity upf to activity upf to activity upf to activity upf ctive at 100 µ ctive at 100 µ ctive at 100 µ	leprotic activ reening agains M. leprae C.R.C. strain to 400 μ g/ml of g/ml concent to 400 μ g/ml of to 400 μ g/ml of to 400 μ g/ml of to 400 μ g/ml of to 400 μ g/ml of g/ml concent to 400 μ g/ml of g/ml concent	st) concentration concentration concentration concentration concentration concentration ration ation			
Compound No. 1 2 3 4 5 6 7 8 9	Growth end of th Conce 10^{-4} + 0 0 0 0 0 0 + + + + 0 0 0 0 + + + + 0 0 0 0	in Youma hree weeks antration of 10 ⁻⁵ ## 0 Sl # # # # # growth # growth # = variou ight growth	n's medi of drug (2 10 ⁶ ## ## ## ## ## ## ## ## ## #	H37Rv strain) um at the Molar) Rv control ## n ## n ## n ## n ## n ## n ## n ##	Anti Scr (I to activity up ctive at 100 μ to activity up to activity up to activity up to activity up ctive at 100 μ to activity up ctive at 100 μ A.J.L. Dapso	leprotic activ reening agains M. leprae C.R.C. strain to 400 μ g/ml of to 400 μ g/ml of the formula of the formula to 400 μ g/ml of the formula of the formula of the formula to 400 μ g/ml of the formula of the fo	st) concentration concentration concentration concentration ration concentration ration ation drug)			

TABLE I

Experimental¹²⁾

N,N'-Bis-(9-acridino)-ethylenediamine Dihydrochloride (IV, n=2)----In a 50 ml round-bottomed flask fitted with a water condenser and a calcium chloride guard tube was placed a mixture of phenol 10 g, 9-chloro-

¹²⁾ The melting points are uncorrected.

	x									
Compound	Formula	Yield (%)	Crystallization solvent	mp (°C)	Analysis (%)					
Compound No. from Table I					Calcd.			Found		
					ć	н	Ň	ć	Н	N
1	$\mathrm{C_{28}H_{22}N_4}{\cdot}\mathrm{2HCl}$	82.0	aqueous ethanol	245 (decomp.)			11.49			11.75
2	$\mathrm{C_{29}H_{24}N_4}{\cdot}\mathrm{2HCl}$	89.0	aqueous ethanol	170 (decomp.)	_		11.17			11.07
3	$\mathrm{C_{30}H_{26}N_4}{\cdot}\mathrm{2HCl}$	93.2	ethanol	255 (decomp.)		—	10.87			10.84
4	${\rm C_{31}H_{28}N_4}{\cdot}{\rm 2HCl}$	75.9	ethanol-ether	250 (decomp.)	—		10.58			10.32
5	$\mathrm{C_{32}H_{30}N_4}{\cdot}\mathrm{2HCl}$	86.5	ethanol-ether	146147			10.31			10.67
6	$\substack{\mathrm{C_{33}H_{32}N_4}\cdot\mathrm{2HCl}\\\cdot\mathrm{H_2O}}$	68.2	ethanol-ether	135—136	68.86	6.26	9.73	68.63	6.70	10.02
7	$\substack{\mathbf{C_{34}H_{34}N_4\cdot 2HCl}\\ \cdot\mathbf{H_2O}}$	91.0	ethanol-ether	154—155	69.26	6.45	9.50	68.79	6.88	9.07
8	$\mathrm{C_{35}H_{36}N_4}{\cdot}\mathrm{2HCl}$	85.4	ethanol-ether	126—127	71.96	6.49	9.57	71.58	6.21	9.78
9	$\substack{\mathrm{C_{36}H_{38}N_4} \cdot 2\mathrm{HCl}\\ \cdot\mathrm{H_2O}}$	86.7	ethanol-ether	130—131	70.01	6.80	9.07	69.86	6.49	8.9
10	$\substack{ C_{38}H_{42}N_4\cdot 2HCl\\\cdot 2H_2O}$	92.5	ethanol-ether	100-101	68.77	7.23	8.44	69.08	6.91	8.6

TABLE II

acridine (0.02 mole) and ethylenediamine (0.01 mole). The flask was heated in an oil bath maintained at $130-135^{\circ}$ for 14—16 hours. After cooling, the contents of the flask were diluted with 40 ml of ether. N,N'-Bis(9-acridino)-ethylenediamine dihydrochloride separated was filtered off and washed with ether. Recrystallisation from aqueous ethanol gave the pure product. Other compounds mentioned in Table I were prepared in a similar manner and their properties are given in Table II. C_3-C_5 -Methylenediamines used herein were prepared according to the procedure described by Putokhin,¹³) and other diamines were obtained from Fluka, Swiss.

Antibacterial Activity (in Vitro against S. aureus and E. coli by Agar-cup Method¹⁴⁾—25 ml of nutrient agar in petridishes was seeded with 0.1 ml of 18 hours old culture. Holes were punched (10 mm diameter) and 0.1 ml of 10^{-2} molar solution of drug was added in each hole.

Antitubercular Activity (*in Vitro* against *M. tuberculosis*, H37Rv strain, by Youman's Method¹⁵))——To a 5 ml of liquid (Youman's medium) 1 loopful (4 mm diameter) of 12-14 days culture was added. Cells were grown as stationary floating cultures. Growth of cells was followed at weekly intervals on Baush and Lomb spectrophotometer.

Antileprotic Activity (in Vitro against M. leprae, I.C.R.C. strain, by Dubo's Method¹⁶))——Drug dilutions ranging from 400 μ g per ml to 3.2 μ g per ml were mixed with 4 ml of Dubo's medium and 1 ml of I.C.R.C. Bacilli (Bapat, et al.¹⁷) 1961) was added to each dilution. Turbidimetric measurements were recorded on a Baush and Lomb spectrophotometer at 620 m μ for 12 days. The growth curve was plotted on graph and the rate of inhibition of bacilli was calculated. The results are recorded in Table I.

Acknowledgement We thank Prof. G.B. Singh, Head of the Department of Chemistry for the facilities and financial assistance to one of us (A.K.S.). We are deeply grateful to Dr. M.B. Bhide, Haffkine Institute, Bombay, and his staff for antileprotic screening. The authors are indebted to Dr. T. Ramakrishnan, Indian Institute of Science, Bangalore, and his staff for antibacterial and antitubercular screening. We wish to thank Mr. V.N. Muley and Mr. P.S. Gurjar for the microanalyses reported.

- 15) G.P. Youman's, Proc. Soc. Exp. Biol. New York, 57, 122 (1944).
- 16) Medical Research Council, Lancet, 2, 862 (1948).

N. Putokhin, Trans. Pure Chem. Reagents (Moscow), No. 6, 10-21 (1927); cf. Chem. Abstract, 23, 2938 (1929); cf. Ber. 59, 625 (1926).

¹⁴⁾ J.H. Humphrey and J. Lightbrown, J. Gen. Microbio., 7, 129 (1952).

¹⁷⁾ Bapat, et al., Int. Jour. of Leprosy, 29, 329-342 (1961).